Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,575,584
  • Shares Outstanding, K 3,098,233
  • Annual Sales, $ 26,617 M
  • Annual Income, $ 3,196 M
  • 60-Month Beta 0.50
  • Price/Sales 6.95
  • Price/Cash Flow 18.60
  • Price/Book 9.98
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 21.09%
  • Historical Volatility 27.44%
  • IV Percentile 18%
  • IV Rank 10.89%
  • IV High 47.36% on 02/03/21
  • IV Low 17.88% on 08/04/21
  • Put/Call Vol Ratio 1.01
  • Today's Volume 7,061
  • Volume Avg (30-Day) 10,879
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 230,519
  • Open Int (30-Day) 204,190

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.66
  • Number of Estimates 4
  • High Estimate 0.73
  • Low Estimate 0.62
  • Prior Year 0.47
  • Growth Rate Est. (year over year) +40.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.13 +9.24%
on 09/17/21
61.34 -1.83%
on 10/11/21
+3.77 (+6.68%)
since 09/15/21
3-Month
55.13 +9.24%
on 09/17/21
61.34 -1.83%
on 10/11/21
+3.26 (+5.72%)
since 07/15/21
52-Week
46.48 +29.56%
on 03/04/21
61.34 -1.83%
on 10/11/21
+7.67 (+14.60%)
since 10/15/20

Most Recent Stories

More News
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer

Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI ® (durvalumab) demonstrated a statistically significant and clinically...

AZN : 60.22 (+0.92%)
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

AZN : 60.22 (+0.92%)
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

AZN : 60.22 (+0.92%)
PFE : 41.49 (-0.43%)
MRNA : 324.21 (-2.31%)
NVAX : 161.95 (-4.59%)
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).

AZN : 60.22 (+0.92%)
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

PPH : 72.94 (+0.62%)
AZN : 60.22 (+0.92%)
BMY : 58.36 (+1.14%)
MRK : 78.33 (unch)
PJP : 77.77 (-0.08%)
IHE : 184.52 (+0.42%)
AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug

If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.

REGN : 553.24 (-0.43%)
AZN : 60.22 (+0.92%)
LLY : 237.88 (+0.50%)
VIR : 39.09 (-2.83%)
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic...

AZN : 60.22 (+0.92%)
Carnival, Alibaba, Myovant rise; Weibo falls

NEW YORK (AP) — Stocks that moved sharply or traded heavily Monday:

CCL : 23.67 (-0.25%)
BABA : 168.00 (+0.73%)
AZN : 60.22 (+0.92%)
PFE : 41.49 (-0.43%)
MYOV : 20.80 (-3.88%)
WB : 47.92 (-1.11%)
AstraZeneca buying drug developer Alexion for $39 billion

LONDON (AP) — Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.

PFE : 41.49 (-0.43%)
ALXN : 182.50 (+1.70%)
AZN : 60.22 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

3rd Resistance Point 60.94
2nd Resistance Point 60.74
1st Resistance Point 60.48
Last Price 60.22
1st Support Level 60.02
2nd Support Level 59.82
3rd Support Level 59.56

See More

52-Week High 61.34
Last Price 60.22
Fibonacci 61.8% 55.66
Fibonacci 50% 53.91
Fibonacci 38.2% 52.16
52-Week Low 46.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar